Colon Cancer Treatment in China: Surgery, FOLFOX Chemotherapy, Bevacizumab, Cetuximab, Fruquintinib, MSI-H Immunotherapy, Liver Metastasis Surgery, HIPEC, RAS BRAF HER2 Biomarker Testing, and MDT Consultation for International Patients and Caregivers Seeking Colorectal Cancer Care in China

This guide covers colon cancer and colorectal cancer treatment options for international patients and families exploring cancer care in China — including colon adenocarcinoma, sigmoid colon cancer, right and left colon cancer, and metastatic colorectal cancer; biomarker profiling including RAS (KRAS/NRAS) mutation testing, BRAF V600E testing, MSI (microsatellite instability) and dMMR (mismatch repair deficiency) testing, HER2 amplification, and NTRK fusion; surgical options including laparoscopic colectomy, liver resection for colorectal liver metastases, conversion therapy, cytoreductive surgery plus HIPEC (hyperthermic intraperitoneal chemotherapy) for peritoneal metastasis; FOLFOX and CAPOX adjuvant and first-line chemotherapy; anti-VEGF bevacizumab (贝伐珠单抗); anti-EGFR therapy cetuximab (西妥昔单抗) for RAS/BRAF wild-type left-sided tumours; BRAF V600E targeted therapy with encorafenib plus cetuximab; China-developed fruquintinib (呋喹替尼/爱优特 by Hutchmed 和黄医药), NMPA and FDA approved for refractory metastatic colorectal cancer; MSI-H/dMMR immunotherapy with pembrolizumab (帕博利珠单抗) and nivolumab; HER2-directed therapy for HER2-amplified colorectal cancer; and structured MDT second opinion consultation for international patients coordinated through ChinaMed Waypoint.

Cancer Care in China
Colon CancerTargeted TherapyImmunotherapyChina-Developed Drugs

Colon Cancer Treatment in China: Targeted Therapy, Surgery, and Access for International Patients

June 10, 2026Treatment Guide · International Patients

China diagnoses more than 500,000 new colorectal cancer cases annually — among the highest volumes in the world — giving Chinese oncologists deep clinical experience across all disease stages and molecular subtypes. For international patients, China offers access to a comprehensive treatment toolkit including China-developed fruquintinib, high-volume liver metastasis surgery, HIPEC programmes for peritoneal disease, and MSI-H immunotherapy — alongside full standard systemic therapy.

Key points for patients and families

  • Biomarker profiling — RAS (KRAS/NRAS), BRAF V600E, MSI/MMR status, HER2, and tumour sidedness — determines which targeted therapies and immunotherapy options are available. These results should be confirmed before any treatment plan is finalised.
  • Fruquintinib (呋喹替尼), a China-developed multi-targeted VEGFR inhibitor developed by Hutchmed, is NMPA-approved for refractory metastatic colorectal cancer and has since received global FDA approval — it was available in China first.
  • MSI-H/dMMR colorectal cancer is highly responsive to PD-1 immunotherapy. Patients who have not undergone MSI/MMR testing should do so, as a positive result significantly changes available treatment options.
  • China’s major cancer centres have extensive experience with liver metastasis surgery and conversion therapy — converting initially unresectable liver metastases to resectable through combination treatment. An MDT consultation can assess whether this pathway is feasible.

Why China's Colorectal Cancer Caseload Matters

Colorectal cancer is one of the most commonly diagnosed cancers in China, with incidence rising rapidly in urban populations — driven by dietary changes, sedentary lifestyles, and improved detection. At major oncology centres in Beijing, Shanghai, and other cities, colorectal cancer specialists routinely manage hundreds of new cases annually, creating deep institutional familiarity with all disease presentations, including complex metastatic cases, liver-limited disease, peritoneal involvement, and rare molecular subtypes.

One clinically distinctive characteristic of colorectal cancer management in China is the emphasis on multidisciplinary case review — including surgical, medical oncology, hepatobiliary, radiation, and radiology perspectives evaluated together before treatment decisions are made. This MDT approach is particularly relevant for patients with liver metastases where the question of surgical resectability is central to the treatment strategy.

For international patients seeking a structured second opinion or MDT review of a colon cancer diagnosis or treatment plan, Chinese specialist teams offer relevant expertise across all treatment phases — from adjuvant chemotherapy decisions after surgery through to complex metastatic disease management and later-line targeted therapy.

Quick Answer

China diagnoses 500,000+ colorectal cancer cases annually. Treatment options include FOLFOX/CAPOX chemotherapy, bevacizumab anti-VEGF, cetuximab anti-EGFR (RAS/BRAF wild-type), MSI-H immunotherapy with pembrolizumab, and China-developed fruquintinib (now also FDA-approved globally) for refractory disease. China's high-volume centres offer liver metastasis surgery, conversion therapy, and HIPEC programmes. International patients can request a remote MDT consultation to assess whether China-specific treatment access or surgical expertise is relevant to their case.

Biomarker Profiling: The Foundation of Colon Cancer Treatment Decisions

Colon cancer treatment — particularly in the metastatic setting — is driven by a tumour's molecular profile. Results from biomarker testing determine which targeted therapies are appropriate, which immunotherapy agents may be effective, and how aggressive initial treatment should be. At experienced Chinese cancer centres, standard testing for metastatic colorectal cancer includes:

RAS (KRAS/NRAS) mutation testing
Mutations in KRAS or NRAS exons 2, 3, and 4 are found in approximately 50–55% of colorectal cancers and exclude patients from anti-EGFR therapy (cetuximab, panitumumab). RAS wild-type status is required for anti-EGFR eligibility. Extended RAS testing — beyond just KRAS exon 2 — is now standard and is performed routinely at major Chinese centres.
BRAF V600E mutation testing
BRAF V600E mutations occur in approximately 8–10% of colorectal cancers and predict poor prognosis with standard chemotherapy. Patients with BRAF V600E-mutated disease are eligible for the encorafenib plus cetuximab combination (BEACON CRC trial), which is available at Chinese oncology centres. BRAF V600E also confers resistance to anti-EGFR therapy alone.
MSI / MMR testing
Microsatellite instability (MSI) testing or mismatch repair deficiency (dMMR) immunohistochemistry identifies approximately 4–5% of metastatic colorectal cancers that are highly responsive to PD-1 immunotherapy. MSI-H/dMMR status is the most important predictive biomarker for immunotherapy eligibility in colorectal cancer, and its identification changes first-line treatment completely.
HER2 amplification
HER2 amplification or overexpression is found in approximately 2–3% of metastatic colorectal cancers — predominantly in RAS/BRAF wild-type tumours. HER2-directed therapy (trastuzumab combinations) is an established option for HER2-amplified colorectal cancer and is available at major Chinese centres. HER2 testing should be considered particularly in RAS wild-type patients who have progressed on standard treatment.
Tumour sidedness (primary tumour location)
Left-sided colon tumours (splenic flexure, descending colon, sigmoid) behave differently from right-sided tumours (caecum, ascending colon, transverse colon) — a distinction now embedded in treatment guidelines. Anti-EGFR therapy is most effective in RAS/BRAF wild-type left-sided disease. Right-sided tumours tend to have worse prognosis and different molecular profiles (higher MSI-H, BRAF V600E frequency).
NTRK fusion and other actionable alterations
NTRK gene fusions — rare, found in <1% of colorectal cancers — are highly responsive to TRK inhibitors (larotrectinib, entrectinib). Next-generation sequencing (NGS) panels performed at Chinese centres identify NTRK fusions and other rare actionable alterations including RET fusions, TMB-high status, and PIK3CA mutations relevant to emerging treatment strategies.

Patients who have received only limited molecular testing — for example, KRAS exon 2 alone without extended RAS, or without MSI/MMR testing — may benefit from comprehensive re-profiling as part of any second opinion or MDT review. Incomplete biomarker data can result in suboptimal treatment selection.

Surgery: Resection, Liver Metastases, and Conversion Therapy

Surgery is central to colon cancer treatment — both for the primary tumour and, where feasible, for metastatic disease. China's high-volume colorectal oncology centres offer the full range of surgical approaches, including laparoscopic and robotic-assisted colectomy as well as complex multi-organ resections.

Primary colon cancer surgery

Surgical resection of the primary tumour — hemicolectomy, sigmoidectomy, or total colectomy depending on tumour location — is the standard curative approach for non-metastatic colon cancer. Minimally invasive laparoscopic colectomy is routine at major Chinese centres, associated with faster recovery and equivalent oncological outcomes compared with open surgery in appropriate patients.

  • Right hemicolectomy — for caecal and ascending colon tumours
  • Left hemicolectomy / sigmoidectomy — for left-sided and sigmoid tumours
  • Total or subtotal colectomy — for hereditary syndromes (Lynch, FAP) or synchronous lesions
  • Robotic-assisted colectomy available at selected major centres

Liver metastasis surgery

Surgical resection of colorectal liver metastases — when feasible — offers the best long-term outcomes for patients with liver-limited stage IV disease. China's hepatobiliary surgery centres have extensive experience with complex hepatic resections, including cases involving multiple lesions, bilobar distribution, and proximity to major hepatic vascular structures.

  • Major hepatic resections including right hepatectomy, left hepatectomy, and trisectionectomy
  • Staged hepatectomy for bilateral disease (ALPPS procedure at selected centres)
  • Thermal ablation (microwave, radiofrequency) for lesions not suitable for resection
  • Transarterial chemoembolisation (TACE) as locoregional therapy
  • Portal vein embolisation to increase future liver remnant before major resection

Conversion therapy for initially unresectable liver metastases

Conversion therapy — using intensive combination chemotherapy and targeted therapy to reduce the size and number of liver metastases until surgical resection becomes feasible — is an established strategy at leading Chinese colorectal oncology centres. The goal is to convert initially unresectable disease into a resectable state. This requires close coordination between medical oncology and hepatic surgery, ideally through structured MDT review.

Why this matters for international patients: Some patients are told that their liver metastases are "unresectable" without a formal MDT assessment by a hepatic surgeon experienced with conversion therapy. A structured second opinion from a high-volume centre may identify cases where conversion is possible.

HIPEC for peritoneal metastasis

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for selected patients with colorectal peritoneal metastasis. China has growing HIPEC programme experience at specialised oncology centres. CRS + HIPEC is a complex procedure associated with significant morbidity, and patient selection — based on peritoneal cancer index (PCI), disease extent, and performance status — requires careful MDT evaluation.

Chemotherapy: Standard Regimens in Colon Cancer

Platinum-oxaliplatin-based and irinotecan-based chemotherapy regimens are the backbone of colon cancer systemic treatment — used in adjuvant therapy after surgery and as first and second-line treatment for metastatic disease. All standard regimens are available at Chinese cancer centres.

FOLFOX
Oxaliplatin + leucovorin + 5-fluorouracil. Standard adjuvant regimen for stage III colon cancer and widely used first-line for metastatic disease combined with bevacizumab or anti-EGFR therapy.
CAPOX / XELOX
Oral capecitabine (卡培他滨) + oxaliplatin. An effective alternative to FOLFOX in the adjuvant and metastatic setting — the oral component offers a more convenient administration schedule for appropriate patients.
FOLFIRI
Irinotecan (伊立替康) + leucovorin + 5-fluorouracil. Second-line standard after oxaliplatin failure in metastatic disease, or used as alternative first-line in certain situations. Often combined with bevacizumab or anti-EGFR therapy.
FOLFOXIRI
Triplet regimen combining oxaliplatin, irinotecan, and 5-FU. Used in selected patients with high disease burden or where rapid tumour response is needed for conversion to resectability. Higher toxicity requires careful patient selection.
Adjuvant treatment decisions
Stage III colon cancer: 6 months of FOLFOX or CAPOX is standard. High-risk stage II: adjuvant chemotherapy may be considered based on risk features (T4, perineural invasion, obstruction/perforation, <12 lymph nodes examined). MSI-H/dMMR stage II: adjuvant chemotherapy with 5-FU alone may be less effective; MDT discussion required.
Duration optimisation
The IDEA collaboration demonstrated that 3 months of CAPOX provides equivalent outcomes to 6 months in low-risk stage III disease with substantially less neuropathy. Personalised duration decisions are made through MDT discussion at leading Chinese centres.

Targeted Therapy: Internationally Approved and China-Developed Agents

Targeted therapy in metastatic colorectal cancer is determined by molecular profile — specifically RAS and BRAF mutation status, tumour sidedness, and HER2 status. China provides access to the full range of internationally approved agents alongside one important China-developed agent.

Anti-VEGF therapy

Bevacizumab (贝伐珠单抗)

Anti-VEGF monoclonal antibody added to first-line FOLFOX or FOLFIRI chemotherapy in metastatic colorectal cancer — applicable regardless of RAS or BRAF mutation status, or tumour sidedness. Bevacizumab combined with FOLFIRI is also standard second-line treatment after oxaliplatin-based first-line therapy (TML trial data). Bevacizumab biosimilars are available in China, improving cost accessibility.

Anti-EGFR therapy (RAS/BRAF wild-type, left-sided)

Cetuximab (西妥昔单抗)

Anti-EGFR monoclonal antibody used in RAS wild-type, BRAF wild-type, left-sided metastatic colorectal cancer — where it provides the greatest benefit added to chemotherapy. Also used in later-line settings and in combination with BRAF inhibitor encorafenib in BRAF V600E-mutated disease. Right-sided RAS wild-type tumours derive much less benefit from anti-EGFR therapy and bevacizumab-based regimens are generally preferred.

BRAF V600E targeted therapy

Encorafenib + Cetuximab

The BEACON CRC Phase III trial established encorafenib (BRAF inhibitor) combined with cetuximab (anti-EGFR) as the standard of care for BRAF V600E-mutated metastatic colorectal cancer after prior therapy. This combination significantly outperformed chemotherapy and is available at leading Chinese oncology centres for eligible patients. BRAF V600E testing is therefore essential before third-line chemotherapy is initiated.

China-developed targeted agent

Fruquintinib (呋喹替尼 / 爱优特)

China-developed · Now FDA-approved

Fruquintinib is a small-molecule inhibitor of VEGFR1, VEGFR2, and VEGFR3, developed by Hutchmed (和黄医药/HUTCHMED). It was NMPA-approved for metastatic colorectal cancer in China based on the FRESCO Phase III trial in Chinese patients, which demonstrated a significant improvement in overall survival after at least two prior lines of chemotherapy. The FRESCO-2 Phase III trial — conducted globally across Asia, Europe, and North America — confirmed the survival benefit in a broader international population and led to FDA approval in 2023.

Relevance for international patients: Fruquintinib was available in China before receiving global approval — patients who had exhausted standard options before 2023 could only access it in China. Even now, pricing and access pathways in China may differ from other markets, and the drug's availability can be discussed as part of an MDT consultation for patients with refractory metastatic colorectal cancer.

HER2-directed therapy (HER2-amplified colorectal cancer)

Trastuzumab + pertuzumab / Trastuzumab + lapatinib

HER2-amplified metastatic colorectal cancer (approximately 2–3% of mCRC, predominantly RAS/BRAF wild-type) responds to HER2-directed antibody combinations. The MOUNTAINEER trial established trastuzumab plus tucatinib as an option in this setting. In China, trastuzumab-based combinations for HER2-amplified colorectal cancer are available within the context of MDT evaluation, and trastuzumab deruxtecan (DS-8201) is being studied in this indication.

Immunotherapy in Colon Cancer: MSI-H / dMMR Is the Key Determinant

The effectiveness of PD-1 checkpoint inhibitor immunotherapy in colorectal cancer is almost entirely determined by MSI/MMR status. MSI-H or dMMR colorectal cancer — found in approximately 4–5% of metastatic cases — responds strongly to immunotherapy. MSS colorectal cancer generally does not.

MSI-H / dMMR metastatic colorectal cancer

For patients with MSI-H or dMMR unresectable metastatic colorectal cancer, pembrolizumab (帕博利珠单抗) is approved as first-line treatment in China and internationally — based on the KEYNOTE-177 trial, which demonstrated significantly longer progression-free and overall survival compared with standard chemotherapy. This is one of the most striking biomarker-driven treatment successes in gastrointestinal oncology.

  • Pembrolizumab (帕博利珠单抗) — first-line monotherapy for MSI-H/dMMR mCRC (KEYNOTE-177 data)
  • Nivolumab + ipilimumab — combination immunotherapy option in MSI-H/dMMR disease
  • China-developed PD-1 inhibitors (tislelizumab 百泽安, sintilimab 信迪利单抗) being studied in MSI-H CRC at Chinese centres
  • Patients with MSI-H disease should discuss first-line immunotherapy before standard chemotherapy

MSI-H in early-stage colon cancer

In early-stage (stage II) colon cancer, MSI-H status has a different significance — it is actually associated with better prognosis and may indicate that adjuvant 5-FU-based chemotherapy provides little benefit. The decision about adjuvant chemotherapy in MSI-H stage II disease is a nuanced MDT discussion. MSI-H also raises the question of Lynch syndrome — an inherited condition requiring genetic counselling and family screening.

MSS colorectal cancer and immunotherapy

Microsatellite stable (MSS) colorectal cancer — which represents approximately 95% of metastatic cases — does not currently respond well to PD-1 inhibitors as single agents. Research is ongoing into combinations that may sensitise MSS tumours to immunotherapy:

  • PD-1 + anti-VEGF combinations — rationale based on bevacizumab's immunomodulatory effects
  • PD-1 + TGF-beta pathway inhibitors — under investigation
  • Bispecific antibodies targeting multiple immune checkpoints — clinical trials at Chinese centres
  • CEA-targeting CAR-T and cell therapy for MSS colorectal cancer — early-stage research

Considering colon cancer treatment options in China?

An online MDT consultation with Chinese colorectal oncology specialists can review your existing pathology, molecular testing (RAS, BRAF, MSI/MMR, HER2), and treatment history — and assess whether liver metastasis surgery, conversion therapy, fruquintinib, or MSI-H immunotherapy in China may be relevant to your case.

Request an online MDT consultation

Metastatic Colon Cancer: How Treatment Is Sequenced

Treatment sequencing in metastatic colorectal cancer is complex and personalised — it depends on biomarker results, performance status, disease burden, goals of treatment, and whether surgical resection is an objective. The following framework reflects how treatment is typically sequenced at experienced Chinese oncology centres.

First-line treatment

MSI-H/dMMR

MSI-H/dMMR: Pembrolizumab monotherapy (KEYNOTE-177)

MSS / All molecular profiles

MSS / RAS wild-type left-sided: FOLFOX or FOLFIRI + cetuximab; MSS / RAS mutated or right-sided: FOLFOX or FOLFOXIRI + bevacizumab

FOLFOXIRI + bevacizumab considered for high-burden disease where conversion to resectability is the goal

Second-line treatment

MSI-H/dMMR

MSI-H/dMMR: Continue immunotherapy or switch agent if progressed

MSS / All molecular profiles

Switch chemotherapy backbone (FOLFIRI after FOLFOX, vice versa) ± bevacizumab continuation (TML trial) or anti-EGFR (if RAS/BRAF wild-type and not yet used)

Bevacizumab continuation beyond progression (TML trial) is established practice in China

Third-line / refractory

MSI-H/dMMR

MSI-H/dMMR: Re-challenge or alternative immunotherapy combination

MSS / All molecular profiles

BRAF V600E mutated: Encorafenib + cetuximab (BEACON CRC); HER2-amplified: HER2-directed therapy; All-comers: Fruquintinib (呋喹替尼) or regorafenib

Fruquintinib (China-developed, now globally approved) is a well-established third-line option in China

For patients with liver-limited stage IV disease, the question of surgical candidacy should be revisited at every treatment response assessment. Conversion from unresectable to resectable is a meaningful treatment goal that should be embedded in the initial plan, and cancer treatment coordination in China can support access to the hepatobiliary surgical expertise needed for this assessment.

MDT Evaluation and Second Opinion for Colon Cancer

Colon cancer treatment decisions — particularly in metastatic disease, where resectability, biomarker-driven targeted therapy, and treatment sequencing all intersect — benefit strongly from multidisciplinary specialist input. Major Chinese cancer centres conduct structured MDT reviews bringing together colorectal oncologists, hepatobiliary surgeons, radiation oncologists, pathologists, and imaging specialists.

An online MDT consultation for colon cancer patients can include:

  • Review of pathology and molecular testing — confirming RAS, BRAF, MSI/MMR status, HER2, and whether any actionable alterations have been missed
  • Assessment of liver metastases — whether surgical resection or conversion therapy should be considered, based on imaging and disease extent
  • Evaluation of treatment sequencing — whether prior treatments have been optimally ordered given molecular profile and tumour sidedness
  • Identification of fruquintinib, BRAF-targeted therapy, or HER2-directed therapy that may be appropriate but not yet used
  • Clinical trial eligibility assessment — including trials of MSS colorectal cancer immunotherapy combinations active at Chinese centres
  • Practical logistics guidance if in-person assessment, liver surgery, or treatment in China is being considered

Supportive Care During Colon Cancer Treatment in China

Major Chinese cancer centres integrate supportive care into active colon cancer treatment programmes. For patients undergoing chemotherapy, targeted therapy, or post-surgical recovery, supportive care addresses common challenges including peripheral neuropathy from oxaliplatin, fatigue, nutritional depletion after surgery, and the psychological burden of metastatic disease management.

Integrative approaches available at Chinese oncology centres — including Traditional Chinese Medicine supportive care — may be offered alongside standard treatment. Acupuncture has been studied for chemotherapy-induced neuropathy, nausea, and cancer-related fatigue. Nutritional support is particularly relevant for colon cancer patients, where the digestive system is directly affected by both the disease and its treatment. These approaches are used as complementary support — not as alternatives to evidence-based colon cancer treatment.

Oxaliplatin neuropathy management
Peripheral neuropathy — numbness, tingling, cold sensitivity — is one of the most clinically significant side effects of oxaliplatin-based chemotherapy. Symptom monitoring and dose modification strategies are integrated into treatment management at experienced centres.
Nutritional rehabilitation
Post-colectomy and during systemic therapy, nutritional assessment and tailored dietary support are part of comprehensive cancer centre care. Colostomy management education is provided where applicable.
Post-surgical recovery support
Following major colorectal surgery or hepatic resection, physiotherapy, early mobilisation, and enhanced recovery after surgery (ERAS) protocols are standard at leading Chinese surgical oncology centres.
Psychological support
Oncology psychology services for patients and caregivers — particularly relevant for international patients far from their home support networks during intensive treatment or recovery periods.

Related Guides

Treatment Guide

Gastric Cancer Treatment in China: Targeted Therapy, Immunotherapy & CAR-T

HER2, Claudin18.2, and PD-1 treatments for gastric cancer — including CT041, the potential world-first solid tumour CAR-T.

Treatment Guide

Lung Cancer Treatment in China: Targeted Therapy, Immunotherapy, and Why Caseload Matters

China's EGFR inhibitors, ALK inhibitors, and PD-1 immunotherapy — including several China-developed drugs not yet available in all other countries.

Supportive Care Guide

How Supportive Care Helps During Cancer Treatment

What supportive care involves and how integrative approaches in China complement active colon cancer treatment and recovery.

Frequently Asked Questions

Why might international patients consider colon cancer treatment or a second opinion in China?

China diagnoses more than 500,000 new colorectal cancer cases annually — one of the highest volumes globally — giving Chinese oncologists extensive caseload experience across all disease stages and molecular subtypes. China also has NMPA-approved targeted therapies including fruquintinib (呋喹替尼), a China-developed multi-targeted VEGFR inhibitor that has since received FDA approval, and extensive experience with complex liver metastasis surgery and conversion therapy. For patients with refractory metastatic disease, MSI-H colorectal cancer, or liver-limited metastases where resection may be achievable, a structured MDT review with Chinese specialists may identify treatment options not yet explored.

What is fruquintinib and why is it relevant for international colon cancer patients?

Fruquintinib (呋喹替尼/爱优特) is a small-molecule inhibitor targeting VEGFR1, VEGFR2, and VEGFR3, developed by Hutchmed (和黄医药) in China. It was NMPA-approved for metastatic colorectal cancer after at least two prior lines of treatment, based on the FRESCO Phase III trial conducted in China. The FRESCO-2 global Phase III trial subsequently confirmed efficacy in a broader international population, leading to FDA approval in 2023. For international patients who have progressed on standard chemotherapy and targeted therapy, fruquintinib may be an important later-line option — and was available in China before many other markets.

Does MSI or dMMR status affect colon cancer treatment in China?

Yes — MSI-H (microsatellite instability-high) or dMMR (mismatch repair-deficient) colorectal cancer is highly responsive to PD-1 checkpoint inhibitor immunotherapy, while MSS (microsatellite stable) disease generally is not. In China, pembrolizumab is approved as first-line treatment for unresectable MSI-H/dMMR metastatic colorectal cancer, based on KEYNOTE-177 data. MSI/MMR testing is routinely performed at major Chinese cancer centres and is an essential part of metastatic colorectal cancer biomarker evaluation. Patients who have not undergone MSI/MMR testing should consider doing so as part of any MDT review — this result significantly changes treatment options.

Can colon cancer liver metastases be treated surgically in China?

Yes. China's major cancer and hepatobiliary surgery centres have extensive experience with liver resection for colorectal cancer metastases — including complex cases involving multiple lesions, bilobar distribution, or proximity to major hepatic structures. Conversion therapy — using intensive chemotherapy and targeted therapy to reduce initially unresectable liver metastases to a resectable size — is an established approach at leading Chinese centres. The decision about surgical candidacy requires MDT discussion between colorectal oncologists, hepatic surgeons, and radiologists.

Can international patients receive colon cancer treatment in China?

Yes, depending on coordination, eligibility, and individual patient factors. Many international patients begin with a remote structured MDT consultation — submitting medical records including pathology, molecular testing, and imaging for specialist review — before making any decisions about travel or treatment arrangements. This allows evaluation of whether treatment options in China, including China-available targeted therapies, liver surgery, or clinical trial access, are relevant to their specific case.

Medical disclaimer

ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. Drug availability, regulatory approvals, and clinical guidelines are subject to change. Treatment decisions for colon cancer should be made in consultation with qualified oncologists, colorectal surgeons, and relevant specialists who have reviewed a patient's individual clinical situation, pathology, molecular testing results, and prior treatment history.

Explore colon cancer treatment options in China

An online MDT consultation gives you structured access to Chinese colorectal oncology specialists who can review your case, assess your molecular profile, evaluate liver metastasis resectability, and outline what treatment options — including China-available agents — may be relevant for your situation.

Request an online MDT consultation

We coordinate with leading colorectal oncologists and hepatobiliary surgeons at major Chinese cancer centres.